Nakamura T, et al. (2002) Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules. Oncogene 21, 22-31 11791173

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y218-p - SHC3 iso2 (human) ▲

Modsite: GDGSDHPyyNSIPSK SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y341‑p, SHC3 iso2 (human): Y218‑p, SHC3 (mouse): Y221‑p, SHC3 (rat): Y341‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE TrkA (human) KINASE EGFR (human) KINASE TrkB (human) KINASE Src (human) KINASE TrkA (human) KINASE Src (human) KINASE TrkB (human) KINASE TrkA (human) KINASE TrkB (human) KINASE EGFR (human) KINASE EGFR (human) KINASE Src (human) Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays RAPGEF1 (human) Induces pull-down assay CRK (human) Induces pull-down assay

Y219-p - SHC3 iso2 (human) ▲

Modsite: DGSDHPyyNSIPSKM SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y342‑p, SHC3 iso2 (human): Y219‑p, SHC3 (mouse): Y222‑p, SHC3 (rat): Y342‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE Src (human) KINASE Src (human) KINASE EGFR (human) KINASE EGFR (human) KINASE Src (human) KINASE EGFR (human) KINASE TrkA (human) KINASE TrkA (human) KINASE TrkB (human) KINASE TrkB (human) KINASE TrkA (human) KINASE TrkB (human) Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays RAPGEF1 (human) Induces pull-down assay CRK (human) Induces pull-down assay

Y256-p - SHC3 iso2 (human) ▲

Modsite: FAGKEQTyyQGRHLG SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y379‑p, SHC3 iso2 (human): Y256‑p, SHC3 (mouse): Y259‑p, SHC3 (rat): Y379‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE TrkA (human) KINASE Src (human) KINASE Src (human) KINASE EGFR (human) KINASE EGFR (human) KINASE TrkB (human) KINASE TrkB (human) KINASE TrkA (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NGF increase EGF increase

Y257-p - SHC3 iso2 (human) ▲

Modsite: AGKEQTyyQGRHLGD SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y380‑p, SHC3 iso2 (human): Y257‑p, SHC3 (mouse): Y260‑p, SHC3 (rat): Y380‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE TrkA (human) KINASE TrkB (human) KINASE EGFR (human) KINASE Src (human) KINASE EGFR (human) KINASE TrkA (human) KINASE Src (human) KINASE TrkB (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NGF increase EGF increase

Y283-p - SHC3 iso2 (human) ▲

Modsite: RQGSSDIySTPEGKL SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y406‑p, SHC3 iso2 (human): Y283‑p, SHC3 (mouse): Y286‑p, SHC3 (rat): Y406‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE Src (human) KINASE EGFR (human) KINASE TrkA (human) KINASE TrkB (human) KINASE EGFR (human) KINASE TrkA (human) KINASE Src (human) KINASE TrkB (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes NGF increase EGF increase Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays RAPGEF1 (human) Induces pull-down assay CRK (human) Induces pull-down assay

Y301-p - SHC3 iso2 (human) ▲

Modsite: PTGEAPTyVNTQQIP SwissProt Entrez-Gene Orthologous residues SHC3 (human): Y424‑p, SHC3 iso2 (human): Y301‑p, SHC3 (mouse): Y304‑p, SHC3 (rat): Y424‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  green monkey, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE TrkB (human) KINASE EGFR (human) KINASE Src (human) KINASE TrkA (human) KINASE EGFR (human) KINASE EGFR (human) KINASE TrkB (human) KINASE TrkA (human) KINASE TrkB (human) KINASE TrkA (human) KINASE Src (human) KINASE Src (human) Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation, phosphorylation Effect of modification (process):  transcription, altered Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays DYN1 (human) Induces pull-down assay GRB2 (human) Induces pull-down assay SOS1 (human) Induces pull-down assay Comments:  ERK activation